AMA study: Pharmacy benefit manager market highly concentrated, integrated with insurers

Oct 13, 2022 - 09:33 PM
Prescription Drug Pricing. Green and white capsules on a pharmacy counter.

The market for pharmacy benefit manager services is highly concentrated, with commercial insurers often sharing ownership in the PBM, according to an analysis released today by the American Medical Association. Based on 2020 data from the commercial insurance market, the study found the 10 largest PBMs share 97% of the market for the three PBM services most used by insurers: negotiating rebates with drug makers, assembling retail pharmacy networks, and administering and processing pharmacy claims.
 
“The American Medical Association already has serious concerns about PBM business practices that can have a detrimental impact on patients’ access to and cost of prescription drugs,” said AMA President Jack Resneck Jr, M.D. “PBM markets require careful scrutiny as less competition and more vertical integration can embolden anti-competitive business practices to the detriment of patients.”
 
AHA has urged the Federal Trade Commission to scrutinize commercial health plans that steer patients to third-party specialty pharmacies in which they have a financial interest, preventing health care providers from procuring and managing the drugs they administer to patients.

Related News Articles

Headline
Agencies to assess U.S. pharmaceutical materials in effort to improve supply chain, domestic manufacturing
The Administration for Strategic Preparedness and Response announced Nov. 3 that it will partner with the Bureau of Industry and Security and the Assistant…
Blog
HHS Analysis Does Not Establish a Causal Link Between Medicaid Provider Taxes and Commercial Premiums
Public
A recent issue brief from the Department of Health and Human Services asserts that Medicaid hospital provider taxes raise employer-sponsored insurance premiums…
Headline
Department of Labor finalizes rule on transparency of PBM fee disclosures 
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025
The median annual net launch price for new prescription drugs increased 35% from 2022 to 2025, to $257,000, according to a report released by the Institute for…
Headline
CMS to remove Marketplace coverage for more than 760,000 as part of anti-fraud efforts
The Centers for Medicare & Medicaid Services will cancel approximately 315,000 enrollments impacting more than 760,000 individuals as part of its anti…
Headline
Survey details ongoing shortage of cancer medications
A survey released Sept. 10 by the National Comprehensive Cancer Network highlights ongoing shortages of cancer medications. All responding cancer centers…